Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy

Th. M. Behr; M. Gotthardt; W. Becker; M. Béhé

doi:10.1055/s-0038-1625644

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2002; 41(02): 71-79
DOI: 10.1055/s-0038-1625644

Originalarbeiten – Original Articles

Schattauer GmbH

Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy

A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen/Marburg Experience^[*] Radio-Iodierung von monoklonalen Antikörpern, Proteinen und Peptiden zur Diagnostik und TherapieEine Übersicht standardisierter, zuverlässiger und sicherer Verfahren im kBq- bis GBq-Bereich zum klinischen Gebrauch in der Göttingen/Marburg-Erfahrung

Th. M. Behr

¹Department of Nuclear Medicine of the Philipps-University, Marburg, Göttingen, Germany

,

M. Gotthardt

¹Department of Nuclear Medicine of the Philipps-University, Marburg, Göttingen, Germany

,

W. Becker

²Department of Georg-August-University, Göttingen, Germany

,

M. Béhé

¹Department of Nuclear Medicine of the Philipps-University, Marburg, Göttingen, Germany

› Author Affiliations

Abstract

Summary

Simple and reliable methodologies for radioiodination of proteins and peptides are described. The labeling systems are easy to assemble, capable of radioiodinating any protein or, with slight modifications, also peptide (molecular mass 1000-300,000) from kBq to GBq levels of activity for use in diagnosis and/or therapy. Furthermore, the procedures are feasible in any nuclear medicine department. Gigabecquerel amounts of activity can be handled safely. The most favored iodination methodology relies on the Iodogen system, a mild oxidating agent without reducing agents. Thus, protein degradation is minimized. Labeling yields are between 60 and 90%, and immunoreactivities remain ≥ 85%. Other radioiodination methods (chloramine-T, Bolton-Hunter) are described and briefly discussed.

Zusammenfassung

Einfache und zuverlässige Methoden zur Radioiodierung von Antikörpern, Proteinen und Peptiden mit Hilfe von Markierungssystemen werden beschrieben, die einfach und in jeder nuklearmedizinischen Abteilung zu handhaben sind. Sie sind zur Markierung von Proteinen und – mit leichten Modifikationen – auch von Peptiden geeignet, erlauben sichere Markierungen im kBqund GBq-Bereich. Das bevorzugte Verfahren beruht auf der Iodogen-Methodik, die ein mild oxidierendes Agens nutzt, so dass Proteindenaturierung weitgehend vermieden wird. Markierungsausbeuten liegen zwischen 60 und 90%, die Immunreaktivitäten liegen bei ≥85%. Andere Iodierungsmethoden (Chloramin-T, Bolton-Hunter) werden beschrieben und kurz diskutiert.

Keywords

Radioimmunotherapy - radioiodination

Schlüsselwörter

Radioimmuntherapie - Radioiodierung

Full Text

References

References
1 Behr T, Becker W, Bair HJ. et al. Comparison of complete versus fragmented ^99mTc-labeled anti-CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer. J Nucl Med 1995; 36: 430-41.
2 Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review “Of Mice and Men”. Hybridoma 1997; 16: 101-7.
3 Behr TM, Sharkey RM, Juweid ME. et al. Phase I/II clinical radioimmunotherapy with an ¹³¹I-labeled anti-CEA murine IgG monoclonal antibody. J Nucl Med 1997; 38: 858-70.
4 Behr TM, Sgouros G, Vougioukas V. et al. Therapeutic efficacy and dose-limiting toxicity of Auger-electron versus beta emitters in radioimmunotherapy with internalizing antibodies: Evaluation of 125I- versus ¹³¹I-labeled CO17-1A in a human colorectal cancer model. Int J Cancer 1998; 76: 738-48.
5 Behr TM, Holler E, Gratz S. et al. CD22 is a suitable target molecule for detection and high-dose, myeloablative radioimmunotherapy with the monclonal antibody LL2 in acute lymphatic leukemia and Waldenström’s macroglobulinemia. Tumor Targeting 1998; 3: 32-40.
6 Behr TM, Memtsoudis S, Vougioukas V. et al. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial. Anticancer Res 1999; 19: 2427-32.
7 Behr TM, Jenner N, Béhé M. et al. Radiolabeled peptides for targeting of cholecystokinin-B/ gastrin receptor expressing tumors: from preclinical development to initial clinical results. J Nucl Med 1999; 40: 1029-44.
8 Behr TM, Wörmann B, Gramatzki M. et al. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti- CD20 antibodies in a broad spectrum of B cell-associated malignancies. Clin Cancer Res 1999; 5: 3304-14.
9 Behr TM, Salib AL, Liersch T. et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res 1999; 5: 3232-42.
10 Behr TM, Gotthardt M, Barth A. et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45: 189-200.
11 Behr TM, Griesinger F, Riggert J. et al. High-dose myeloablative radioimmunotherapy of mantle cell non-Hodgkin’s lymphoma with the ¹³¹I-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support: results of a pilot study. Cancer, in press.
12 Behr TM, Liersch T, Greiner-Bechert L. et al. Radioimmunotherapy of small volume disease of metastatic colorectal cancer: results of a phase-II trial with the ¹³¹I-labeled humanized anti-CEA antibody, hMN14. Cancer, in press.
13 Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem J 1973; 133: 529-39.
14 Dewanjee MK. Radioiodination: Theory, practice, and biomedical application. Boston, Dordrecht, London: Kluwer Academic Publishers; 1992
15 Fraker PJ, Speck Jr JC. Protein and cell membrane iodinations with a sparingly soluble chloramide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycoluril. Biochem Biophys Res Commun 1978; 80: 849.
16 Gotthardt M, Fischer M, Baltes N. et al. Scintigraphic detection of insulinomas by [I123]-glucagon-like peptide-1 and its analogon [I123]-exendin4 [Y39] in a rat tumor model. J Nucl Med 2000; 41 Suppl 9P.
17 Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 1962; 194: 495.
18 Kaminski MS, Zasadny KR, Francis IR. et al. Radioimmunotherapy of B-cell lymphoma with [¹³¹I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459-65.
19 Lindmo T, Boven E, Cuttitta F. et al. Determination of the immunoreactive fraction of radiolabeled antibodies by linear extrapolation to binding at infinite antigen excess. J Immunol Methods 1984; 72: 77-89.
20 Lindmo T, Bunn Jr PA. Determination of the true immunoreactive fraction of monoclonal antibodies after radiolabeling. Methods Enzymol 1986; 121: 678-91.
21 Mattes MJ. Limitations of the Lindmo method in determining antibody immunoreactivity. Int J Cancer 1995; 61: 286-8.
22 Press OW, Eary JF, Appelbaum FR. et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219-24.
23 Press OW, Eary JF, Appelbaum FR. et al. Phase II trial of ¹³¹I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1995; 346: 336-40.
24 Press OW, Eary JF, Appelbaum FR. et al. Treatment of relapsed B cell lymphoma with high-dose radioimmunotherapy and bone marrow transplantation. In: Goldenberg DM. (ed). Cancer therapy with radiolabeled antibodies. Boca Raton, Ann Arbor, London, Tokyo: CRC Press; 1995. pp. 229-37.
25 Sharkey RM, Juweid M, Shevitz J. et al. Evaluation of a CDR-grafted (humanized) anti-carcinoembryonic antigen (CEA) monoclonal antibody in preclinical and clinical studies. Cancer Res 1995; 55: 5935-45.
26 Sharkey RM, Behr TM, Mattes MJ. et al. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22. Cancer Immunol Immunother 1997; 44: 179-88.
27 Weadock KS, Sharkey RM, Varga DC. et al. Evaluation of a remote radioiodination system for radioimmunotherapy. J Nucl Med 1990; 31: 508-11.